Health Grants for Schools & universities

National Institutes of Health · Up to $100K

This NIH (R03) opportunity funds pilot projects generating preliminary data on a defined list of understudied proteins associated with rare diseases. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $100,000.

National Institutes of Health · Amount varies

This NIDDK (R21) opportunity funds basic and translational pilot research on biological, behavioral, and social mechanisms contributing to HIV pathogenesis within NIDDK's mission. It is intended for research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Up to $200K

This NIH (R21) opportunity funds research developing novel screening approaches or therapies for fatal or disabling conditions identified through newborn screening, including high-priority genetic conditions. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. The maximum award is about $200,000.

National Institutes of Health · Amount varies

This NIH (R01) opportunity funds research developing novel screening approaches or therapies for fatal or disabling conditions identified through newborn screening, including high-priority genetic conditions. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH (R21) opportunity funds basic, mechanistic research into the biological and genetic causes of cancer health disparities, including new methods, models, and secondary data analyses. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Up to $300K

This NIH (R01) opportunity funds basic research into the harmful effects of acute exposure to ultra-potent synthetic opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations, including delayed effects. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $300,000.

National Institutes of Health · Amount varies

This NIH (R01) opportunity funds innovative analysis of existing social, behavioral, administrative, and neuroimaging datasets to study substance-use behaviors, related disorders, prevention, and health-service use. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH (R21) opportunity funds innovative analysis of existing social, behavioral, administrative, and neuroimaging datasets to study substance-use behaviors, related disorders, prevention, and health-service use. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R61/R33) phased opportunity funds medical device prototype design and testing, disease-target identification, and assay development for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R33) opportunity funds early-stage translational work to optimize medical device prototypes, develop diagnostic assays, and create research tools for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Up to $350K

This NHLBI Catalyze (R33) opportunity funds rigorous validation of transformative, multi-use platforms or technologies that can advance detection, diagnosis, treatment, or prevention of heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $350,000.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R61/R33) phased opportunity funds target identification and validation plus preliminary product or lead-series identification for small molecules, biologics, and combination products treating heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R33) opportunity funds early-stage translational work to identify and characterize therapeutic candidates and combination products (small molecules and biologics) for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIDCR (UG3/UH3) cooperative agreement funds planning and implementation of drug, biologic, device, or procedure intervention clinical trials within NIDCR's mission. A clinical trial is required. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH SHINE (R01) opportunity supports innovative basic and early translational research in nonmalignant hematology, relevant to NIDDK, NIA, and NHLBI missions. It is intended for research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIDCR (UH3) opportunity funds competing renewal or competitive revision of ongoing clinical trials already supported by NIDCR; a clinical trial is required. Because it continues existing NIDCR-funded trials, it is effectively limited to current grantees and not open to new projects. It is aimed at research and academic institutions; foreign organizations are not eligible. No specific award amount is stated.

National Institutes of Health · Up to $500K

This NIDCR (UG3/UH3) cooperative agreement funds planning and implementation of behavioral and social intervention clinical trials for dental, oral, or craniofacial conditions, with a milestone-driven planning phase before transition to a full trial. A clinical trial is required. It is aimed at research and academic institutions; foreign organizations are not eligible. The maximum award is about $500,000.

National Institutes of Health · Up to $50K

The NIH parent Small Research Grant (R03, clinical trial not allowed) supports small, short-term projects such as pilot and feasibility studies, secondary data analysis, and methodology development. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. The award is capped at about $50,000. The small budget suits research institutions pursuing limited-scope projects to generate preliminary data.

National Institutes of Health · Up to $200K

This NIH ORIP (R21) opportunity funds research to develop, improve, and preserve animal models and related biological materials with broad applicability across multiple NIH institutes; single-disease or single-institute projects are out of scope. It is aimed at research and academic institutions; foreign organizations are not eligible. The maximum award is about $200,000.

National Institutes of Health · Amount varies

This NIH (R61/R33) opportunity funds discovery and early evaluation of candidate biomarkers for neurological and neuromuscular disorders, requiring preliminary human-sample evaluation. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.